摘要
目的观察冻干重组人脑利纳肽在急诊治疗急性心力衰竭的临床疗效。方法 96例急性心力衰竭患者随机分为新活素组48例和对照组48例,两组患者均给予标准的抗心力衰竭治疗。新活素组加用冻干重组人脑利纳肽,首次负荷剂量为1.5μg/kg,静脉注射,然后按0.01μg/(kg.min)剂量持续静脉泵入,连续用药48小时,观察患者治疗前和治疗后48小时的临床症状、心率、血压及左室射血分数(LVEF)等情况,测定血浆中N-末端脑利纳肽前体(NT-proBNP)的浓度。结果新活素组的显效率和总有效率均显著优于对照组(P<0.01)。两组治疗后48小时心率、血压及左室射血分数、血浆NT-proBNP浓度均较治疗前明显改善(P<0.05)。新活素组治疗后48小时各项指标的变化较对照组改善得更加显著(P<0.05),特别是NT-proBNP浓度的改变。结论冻干重组人脑利纳肽可以显著改善急性心力衰竭患者的临床症状和心功能,降低血浆中NT-proBNP浓度。
Objective To explore the clinical curative effect of recombinant human brain natri-uretic peptide on acute heart failure in Amercency.Methods Ninety-six patients with acute heart failure were randomly divided into the Xinhuosu group（48 patients）and the control group（48 patients）.The patients in both groups were given standard anti-heart failure therapy.The Xinhuosu group was added rhBNP.For the first time loading dose of 1.5μg/kg intravenous injection,and then press 0.01μg/（kg·min）dose continuous intravenous pump,continuous medication 48h.Observed the clinical symptoms,heart rate,blood pressure,left ventricular ejection fraction（LVEF）,and the plasma NT-proBNP concentration in patients before and 48h after treatment.Results The efficiency and the total effective rate of the Xinhuosu group was significantly better than that of control group（P0.01）.The before treatment of heart rate,blood pressure,LVEF,NT-proBNP concentration of two groups changed significantly 48h after treatment（P0.05）.The indexe 48h after treatment of the Xinhuosu group changed more significantly than that of the control group（P0.05）,especially changed in NT-proBNP concentration.Conclusion The rhBNP could significantly improve the clinical symptoms and cardiac function in patients with acute heart failure and reduce plasma NT-proBNP concentraton.
出处
《辽宁医学杂志》
2012年第1期1-3,共3页
Medical Journal of Liaoning
